Close Menu

NEW YORK ─ Luminex on Wednesday announced preliminary financial results for the second quarter of 2020, saying it anticipates revenues would increase more than 30 percent over Q2 2019, driven by pandemic-related sales across all respiratory and COVID-19 products.

For the three months ended June 30, the molecular diagnostics firm said its revenues would be between $109 million and $110 million compared to the $83.1 million that it reported for the prior-year quarter.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Washington Post reports that US states and territories are seeking more funding for the distribution of SARS-CoV-2 vaccines.

The strain now accounts for about 80 percent of cases in Wales and Scotland, and about half of cases in England, the Guardian reports.

A new study suggests that using CRISPR to edit human embryonic DNA can lead to the loss of whole chromosomes, as the Associated Press reports.

In Science this week: ancient dog genomes highlight long ties with humans, genomic analysis of 40,000-year-old early East Asian individual, and more.